Drugs / dl-Methylphenidate
dl-Methylphenidate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04603391 | Feb → Dec 2021 | — | University of Florida | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dl-Methylphenidate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04603391 ↗ |
| Known as | methylphenidate | “The aim of this study was to evaluate effect of CBD on the disposition of the CES1 substrate methylphenidate (MPH).” NCT04603391 ↗ |
| Known as | MPH | “The aim of this study was to evaluate effect of CBD on the disposition of the CES1 substrate methylphenidate (MPH).” NCT04603391 ↗ |
| Route | Oral | “one 10 mg tablet of dl-methylphenidate (Ritalin®) orally in a fed state” NCT04603391 ↗ |